News

Novadip reports promising interim results from its first-in-human proof-of-concept trial with NVDX3, a stem-cell derived bone graft alternative

Novadip reports promising interim results from its first-in-human proof-of-concept trial with NVDX3, a stem-cell derived bone graft alternative

Novadip Biosciences, a clinical stage biotechnology company specializing in regenerative medicine, has announced positive interim results from its first-in-human clinical trial, NVDX3-CLN01, assessing the safety and efficacy of NVDX3 to heal distal radius fractures in adults. Originating from Novadip’s 3M3 platform, NVDX3 is an allogeneic bone grafting material created from human

Read More
Phase Four announces monopropellant multi-mode propulsion systems

Phase Four announces monopropellant multi-mode propulsion systems

Phase Four, a leading provider of next-generation electric propulsion (EP) solutions for satellites, has announced the planned commercialization of their monopropellant multimode capability.  Using their Maxwell Block III, Phase Four meets electric propulsion performance for a variety of mission profiles, using either ASCENT or hydrazine chemical propellants. Phase Four anticipates

Read More
Ventyx Biosciences announces late-breaking abstract highlighting high rates of clinical and endoscopic remission among LTE completers at Week 52

Ventyx Biosciences announces late-breaking abstract highlighting high rates of clinical and endoscopic remission among LTE completers at Week 52

Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, has announced that a late-breaking abstract including new long-term extension (LTE) data from the Phase 2 trial of tamuzimod in ulcerative

Read More
Achronix releases groundbreaking Speedster AC7t800 Mid-Range FPGA, driving innovation in AI/ML, 5G/6G and Data Center Applications

Achronix releases groundbreaking Speedster AC7t800 Mid-Range FPGA, driving innovation in AI/ML, 5G/6G and Data Center Applications

Achronix Semiconductor Corporation, a leader in FPGA-based hardware accelerator devices and high-performance eFPGA IP, has announced the availability and shipment of AC7t800 FPGA, designed to address the rapidly growing needs of data-centric applications such as generative AI, DPUs and SmartNICs. With samples available today and units already shipped to customers,

Read More
Ventyx Biosciences announces $27 million strategic investment from Sanofi

Ventyx Biosciences announces $27 million strategic investment from Sanofi

Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, has announced that Sanofi has agreed to make a $27 million strategic investment in the Company at an as-converted price of

Read More
PlanetiQ awarded $6.5 Million NOAA contract to supply Radio Occultation data for the commercial weather pilot data program

PlanetiQ awarded $6.5 Million NOAA contract to supply Radio Occultation data for the commercial weather pilot data program

PlanetiQ, a leading innovator of global atmospheric observing systems, has been awarded a Delivery Order (DO-4) contract valued at over $6.5M to supply the National Oceanic and Atmospheric Administration (NOAA) with their proprietary radio occultation (RO) data for a period of one year beginning September 18, 2024. “In addition to

Read More
Ventyx Biosciences announces initiation of dosing in a Phase 2a trial of VTX3232 in patients with early Parkinson’s disease

Ventyx Biosciences announces initiation of dosing in a Phase 2a trial of VTX3232 in patients with early Parkinson’s disease

Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, has announced that the first patient has been dosed in a Phase 2a trial of VTX3232 in patients with early Parkinson’s

Read More
Vascular Therapies completes enrollment in the ACCESS 2 study, a Phase III multinational randomized clinical trial of the Sirolimus Eluting Collagen Implant (Sirogen™) for the surgical creation of arteriovenous fistula for hemodialysis vascular access

Vascular Therapies completes enrollment in the ACCESS 2 study, a Phase III multinational randomized clinical trial of the Sirolimus Eluting Collagen Implant (Sirogen™) for the surgical creation of arteriovenous fistula for hemodialysis vascular access

Vascular Therapies, a biotechnology company focused on improving vascular access outcomes in patients with kidney disease, has announced completion of enrollment in the ACCESS 2 trial, a Phase III prospective randomized, multicenter clinical study of Sirogen™ for the surgical creation of arteriovenous (AV) fistula in patients requiring hemodialysis vascular access.

Read More
Ventyx Biosciences announces results from the Phase 2 trial of VTX958 in participants with moderately to severely active Crohn’s disease

Ventyx Biosciences announces results from the Phase 2 trial of VTX958 in participants with moderately to severely active Crohn’s disease

Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, has announced results from the Phase 2 trial of its allosteric TYK2 inhibitor VTX958 in participants with moderately to severely active

Read More
Emporos and InterLink AI Partner, develop only POS-Integrated lighted will-call solution

Emporos and InterLink AI Partner, develop only POS-Integrated lighted will-call solution

Emporos, the industry’s leading Pharmacy Commerce System including Point of Sale (POS), and InterLink AI, creator of scripClip, a state-of-the-art, lighted pharmacy will-call system, are delighted to announce they have entered a strategic partnership. Pharmacies now have access to a POS-integrated lighted will-call solution for streamlined prescription will-call, checkout, and

Read More
Phase Four partners with Redwire to expand space propulsion offerings and deliver Hall Effect Thrusters

Phase Four partners with Redwire to expand space propulsion offerings and deliver Hall Effect Thrusters

Phase Four, a leading provider of next generation electric propulsion solutions for satellites, proudly announces the signing of a strategic cooperation agreement with Redwire Space (Redwire). This partnership aims to build and deliver Hall Effect Thrusters (HETs) to both government and commercial markets, enhancing the company's capabilities and expanding our

Read More
Primemas selects Achronix embedded FPGA technology for System-on-Chip (SoC) Hub Chiplet platform

Primemas selects Achronix embedded FPGA technology for System-on-Chip (SoC) Hub Chiplet platform

Achronix Semiconductor Corporation, a leader in high-performance FPGAs and embedded FPGA (eFPGA) IP, and Primemas, a fabless semiconductor company developing an innovative SoC Hub Chiplet (Hublet) platform using chiplet technology, has announced a collaboration to bring FPGA programmability to the Primemas suite of products. Primemas chose the Speedcore™ eFPGA IP

Read More